本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
HIGHLIGHTS Topline data from Clarity's diagnostic Phase II trial, DISCO, confirms that 64Cu-SARTATE is safe and highly effective compared to standard-of-care (SOC) imaging at detecting lesions in patients with neuroendocrine tumours (NETs). DISCO compared the diagnostic performance of 64Cu-SARTATE at an average of 4 hours (between 3 to 5 hours) and 20 hours post-administration (same-day and next-day imaging, respectively) to 68Ga-DOTATATE. 64Cu-SARTATE lesion detection substantially outperformed that of 68Ga-DOTATATE. 64Cu-SARTATE detected 393 to 488 lesions, and 68Ga-DOTATATE identified 186 to 265 lesions among 45 study participants across the readers. Out of all the lesions identified by the readers, 230-251 were deemed to be discordant (i.e. only present on one of the scans, 68Ga-DOTATATE or 64Cu-SARTATE positron emission tomography [PET] / computed tomography [CT]). Of these lesions, 93.5% (average across readers) were only detected on the 64Cu-SARTATE PET/CT scans. The number of discordant lesions detected by 64Cu-SARTATE on the same-day and next-day scans was comparable. Approximately half of all the discordant lesions had an available standard-of-truth (SOT), such as histopathology or conventional imaging. The identified discordant lesions yielded a lesion-level sensitivity of 93.4% to 95.6% (95% confidence interval [CI]: 65.1, 99.5) for 64Cu-SARTATE (across both timepoints) and only 4.4% to 6.6% (95%CI: 0.5, 34.9) for 68Ga-DOTATATE across both readers. 64Cu-SARTATE was deemed safe and well tolerated. Only 7 (15.6%) participants experienced 64Cu-SARTATE-related adverse events (AEs). No serious treatment-emergent AEs were observed in the study. Based on the exciting preliminary results of the DISCO trial, Clarity will commence next steps to conduct a registrational Phase III study of 64Cu-SARTATE in NETs with the US Food and Drug Administration's (FDA) guidance. SYDNEY, June 5, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce positive results from the diagnostic Phase II DISCO trial (NCT04438304)[1] with 64Cu-SARTATE in patients with known or suspected NETs. DISCO trial design DISCO is a "Diagnostic Imaging Study of 64COpper-SARTATE Using PET on Patients with Known or Suspected Neuroendocrine Tumours". It assessed the performance of Clarity's SARTATE imaging product as a potential new method to diagnose and manage NETs. The trial aimed to build on earlier clinical experience with 64Cu-SARTATE in patients with NETs, which demonstrated that the diagnostic has excellent imaging characteristics and suggested that 64Cu-SARTATE PET/CT provides comparable or superior lesion detection to 68Ga-DOTATATE PET/CT in all patients, especially in the liver[2]. DISCO recruited participants with Gastroenteropancreatic NETs (GEP-NETs) across 4 sites in Australia, comparing the diagnostic performance of 64Cu-SARTATE PET at an average of 4 hours (between 3 and 5 hours) and approximately 20 hours post-administration (same-day and next-day imaging, respectively) to the current SOC, 68Ga-DOTATATE PET. Participants were required to have undergone a pre-study 68Ga-DOTATATE PET/CT scan within 5 weeks, but not closer than 6 hours prior to the administration of 64Cu-SARTATE as part of their routine clinical care. The trial was initially designed to enrol up to 63 patients, based on the anticipated lesion-level discordance rate between 64Cu-SARTATE and 68Ga-DOTATATE PET. Following a pre-planned early analysis of the data collected during the study, the sample size was adjusted to 45 patients, allowing for an earlier enrolment completion. Study participants were dosed with 200 MBq of 64Cu-SARTATE. Both the 64Cu-SARTATE and 68Ga-DOTATATE PET/CT scans were reviewed by 2 blinded central readers. Participants were followed for up to 12 months to complete additional investigations (e.g. biopsy and conventional imaging) and obtain the SOT used to verify discordant findings between the scan pairs. The verification of discordant findings against the SOT evidence (as true- or false-positive findings) was completed by an independent central assessor, distinct from the central readers evaluating the 64Cu-SARTATE and 68Ga-DOTATATE scans. Lesion-level sensitivity was calculated for the discordant lesions between the scan pairs, with each true-positive discordant lesion on one scan considered a false-negative lesion on the other scan, and each false-positive discordant lesion on one scan considered a true-negative lesion on the other scan. Topline results The results indicate that lesion detection by 64Cu-SARTATE (regardless of imaging timepoint) substantially outperformed that of 68Ga-DOTATATE. 64Cu-SARTATE detected 393 to 488 lesions, and 68Ga-DOTATATE identified 186 to 265 lesions among 45 participants across the readers (Figure 1). Figure 1: 59-year-old participant with functional NETs. 68Ga-DOTATATE PET/CT was performed 26 days prior to the 64Cu-SARTATE PET/CT (same-day imaging). PET (top images): top left image shows higher background on the 68Ga-DOTATATE PET. Top centre and right PET images show multiple lesions detected by 64Cu-SARTATE against a low background. Images are shown as maximum intensity projections. PET/CT fusion (bottom images): axial sections show intense liver uptake on the 68Ga-DOTATATE PET/CT (bottom left), which limits the ability to distinguish lesions from the background, and 3 clearly defined lesions are visible on the 64Cu-SARTATE PET/CT (arrows; bottom centre and right images, same-day and next-day imaging, respectively). Mean maximum standardised uptake value (SUVmax) of lesions shown in the 64Cu-SARTATE PET/CT images: 16.1 and 16.5 on same-day and next-day imaging, respectively. Lesions in the liver have been verified as true-positive based on other scans, including diagnostic CT and magnetic resonance imaging (MRI). Fused images are shown with consistent scaling for visual comparison. Out of all lesions identified by the readers, 230-251 were deemed to be discordant between 64Cu-SARTATE and 68Ga-DOTATATE PET/CT, with 93.5% (average across readers and imaging days) of these discordant lesions detected on the 64Cu-SARTATE scans only. A previously completed Phase I study demonstrated a 1.7 fold increase (median of 6.70 vs. 3.92, p=0.002) in contrast (i.e. lesion-to-background ratio) for 64Cu-SARTATE PET/CT performed at 4 hours post-administration compared to 68Ga-DOTATATE PET/CT2. This improvement in contrast may explain the detection of additional lesions observed in the DISCO trial. The average SUVmax, representing the highest concentration of 64Cu-SARTATE uptake in lesions, was notably high, ranging from 37.42 to 43.90 across both imaging days in the DISCO trial. Approximately half of all discordant lesions had an available SOT, which yielded a lesion-level sensitivity of 93.4% to 95.6% (95%CI: 65.1, 99.5) for 64Cu-SARTATE, including both timepoints, and only 4.4% to 6.6% (95%CI: 0.5, 34.9) for 68Ga-DOTATATE. 64Cu-SARTATE was deemed safe and well tolerated. Only 7 (15.6%) trial participants experienced 64Cu-SARTATE-related AEs, the majority of which were mild (Grade 1) gastrointestinal events, commonly observed in NET patients, and typically resolved within 2 days of onset. No serious treatment-emergent AEs were observed in the study. Based on the findings of the DISCO trial to date, Clarity will commence the next steps to conduct a registrational Phase III study of 64Cu-SARTATE in NETs with the US FDA's guidance. Clarity's Executive Chairperson, Dr Alan Taylor, commented, "We are very excited about the initial topline data from the DISCO trial as 64Cu-SARTATE was confirmed to be safe and very effective in detecting NET lesions in patients with known or suspected disease. The DISCO trial demonstrates a significant advantage of our diagnostic over 68Ga-DOTATATE. 64Cu-SARTATE detected almost double the number of lesions compared to the SOC, and, where SOT was available, a very high lesion-level sensitivity of 93.4% - 95.6% in comparison to just 4.4% - 6.6% for 68Ga-DOTATATE for these discordant findings. In addition to identifying more lesions with our product, lesions detected by 64Cu-SARTATE also exhibited high uptake with low background on the PET scans, making it easier to identify those lesions by readers. Excellent lesion visualisation was also supported by substantial clearance from the liver. The favourable biodistribution of 64Cu-SARTATE PET enabled high-contrast diagnostic imaging for up to approximately 24 hours post-injection (Figure 1), offering greater flexibility in the scheduling of PET/CT scans. "In the DISCO trial, we continue to observe the substantial limitations of the current-generation of short half-life isotope products, what we call isotope-centric medicine. This is clearly illustrated by 68Ga-DOTATATE with imaging timepoints solely dictated by the very short isotope half-life (approximately 1 hour for gallium-68) as opposed to good science and medicine. In contrast, 64Cu-SARTATE highlights the extraordinary benefits of next-generation patient-centric medicine, where imaging is guided by the optimal timepoint to scan and detect lesions, focusing on the needs of the patients and their treating professionals. "We believe that the flexibility of imaging with 64Cu-SARTATE, in comparison to approximately 1 hour with 68Ga-DOTATATE, plays an important role in the detection benefits seen in the DISCO study. We have known this for many years and have demonstrated these advantages of optimal timepoint imaging with different products in our Targeted Copper Theranostic (TCT) platform, including SARTATE. We have seen first-hand in a number of clinical trials that once radiopharmaceutical products are administered, they take time to find the lesion whilst also needing to clear from non-target organs, providing greater contrast. This is known as signal-to-noise ratio or, in our case, tumour-to-background ratio. Having greater contrast is especially important to identify smaller or more difficult to find cancers. "The longer half-life of copper-64, combined with Clarity's proprietary SAR Technology, sets up a strong foundation for next-generation diagnostics, which could be unmatched in the radiopharmaceutical sector. In addition to clinical benefits, the opportunity for high-volume centralised manufacturing and broad, on-demand distribution of ready-to-use diagnostics translates into flexibility and reliability for patients and their treating staff, meaning that every patient with access to PET imaging, including those in underserved and broad geographic areas, may access improved cancer diagnostics. "Patients with NETs are often misdiagnosed and experience delays in receiving the correct diagnosis, which may lead to disease progression and identification of their cancer at later stages. Visualising NET lesions earlier and more accurately may have a significant impact on patient outcomes as it equips clinicians with crucial information on disease burden, helping to determine an optimal treatment plan. As such, the SSTR2 imaging market is an important focus for Clarity. We estimate the NET diagnostic market in the US alone to be around 100,000 scans per year, growing to approximately 120,000 scans per year by 2029. "Importantly, the positive results of the DISCO trial open broader opportunities for the development of 64Cu-SARTATE in additional SSTR2-expressing malignancies beyond NETs, such as certain types of breast and lung cancers, where unmet clinical needs remain high. We believe the SSTR2 market is set to grow substantially with a number of therapies in development for this target, which include large indications such as breast and lung cancers. Subject to the successful completion of these studies, we believe that the imaging market for 64Cu-SARTATE could be as large, if not larger, than the very lucrative prostate cancer imaging market where radiopharmaceuticals currently dominate the diagnostic paradigm. "We look forward to sharing additional data readouts from the trial and presenting the results at future international medical conferences. We plan to rapidly progress discussions with the FDA to initiate a diagnostic registrational Phase III study, as a first key step in expanding SARTATE into the theranostic field of NETs, as well as other SSTR2-expressing cancers, with the copper-64/copper-67 pair. If the findings from the DISCO trial are substantiated in a registrational Phase III study and lead to regulatory approval by the US FDA, 64Cu-SARTATE may play an important role in improving diagnostic accuracy, lesion detection and staging of patients with NETs. These factors could improve clinical decision-making and treatment outcomes, potentially positioning 64Cu-SARTATE as a best-in-class agent for the diagnosis of NETs." About SARTATE SARTATE is a next generation, highly targeted theranostic radiopharmaceutical. It is being developed for diagnosing, staging and subsequently treating cancers that express SSTR2, such as NETs. Like all Clarity products, the SARTATE product can be used with copper-64 (64Cu) for imaging (64Cu-SARTATE) or copper-67 (67Cu) for therapy (67Cu-SARTATE). Disclaimer 64Cu-SARTATE is an unregistered product. The safety and efficacy of 64Cu-SARTATE has not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that this product will become commercially available. About NETs NETs, also known as well-differentiated neuroendocrine neoplasms or carcinoids, represent a heterogeneous group of malignant transformations of cells of the diffuse neuroendocrine system[3]. They most commonly occur in the gastrointestinal tract (48%), lung (25%), and pancreas (9%), but may also originate in other areas, including the breast, prostate, thymus and skin[4]. NETs can either be benign or malignant, as well as non-functional and functional[5]. NETs traditionally have been considered uncommon; however, the incidence has been increasing as a worldwide phenomenon[6]. Overall, it is estimated that more than 20,000 people in the United States are diagnosed with a NET each year[7], and approximately 190,000 people are living with this diagnosis[8]. Patients with NETs present with subtle clinical symptoms, which can lead to a delay in diagnosis of more than 4 years[9]. As such, about 30-75% of NET patients have distant metastases at the time of diagnosis[10]. A 10-year relative survival rate for patients with metastatic GEP-NETs is 3–36%[11]. About Clarity Pharmaceuticals Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers. www.claritypharmaceuticals.com For more information, please contact: Clarity Pharmaceuticals Dr Alan Taylor Lisa SadetskayaExecutive Chairperson Director, Corporate Communicationsataylor@claritypharm.com lisa@claritypharm.com References [1] ClinicalTrials.gov Identifier: NCT04438304 https://clinicaltrials.gov/ct2/show/NCT04438304 [2] Hicks R et al. First-in-human trial of 64Cu-SARTATE PET imaging of patients with neuroendocrine tumours demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. The Journal of Nuclear Medicine. 2019. [3] Cheung VTF, Khan MS. A guide to midgut neuroendocrine tumours (NETs) and carcinoid syndrome. Frontline gastroenterology. 2015;6(4):264-269. [4] Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121(4):589-597. [5] Yau H, Kinaan M, Quinn SL, Moraitis AG. Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives. Biologics : targets & therapy. 2017;11:115-122. [6] Leoncini E, Boffetta P, Shafir M, Aleksovska K, Boccia S, Rindi G. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine. 2017 Nov;58(2):368-379. doi: 10.1007/s12020-017 1273-x. Epub 2017 Mar 16. PMID: 28303513; PMCID: PMC5671554. [7] Wu C, Song Z, Balachandra S, Dream S, Chen H, Rose JB, Bhatia S, Gillis A. Charting the Course: Insights into Neuroendocrine Tumor Dynamics in the United States. Ann Surg. 2025 Jun 1;281(6):968-975. doi: 10.1097/SLA.0000000000006331. Epub 2024 May 6. PMID: 38708616; PMCID: PMC11538379. [8] Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589. PMID: 28448665; PMCID: PMC5824320. [9] Basuroy R, Bouvier C, Ramage JK, Sissons M, Srirajaskanthan R. Delays and routes to diagnosis of neuroendocrine tumours. BMC Cancer. 2018 Nov 16;18(1):1122. doi: 10.1186/s12885-018-5057-3. PMID: 30445941; PMCID: PMC6240263. [10] Aluri V. and Dillion, J.S. 2017, "Biochemical Testing in Neuroendocrine Tumors", Endocrinology & Metabolism Clinics of North America, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777173/ [11] Polee, I.N. et al. 2022, "Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study", European Journal of Cancer, Volume 172, 2022, Pages 252-263, ISSN 0959-8049, https://doi.org/10.1016/j.ejca.2022.06.003. • Krasnovskaya et al. Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals. Int J Mol Sci. 2023 May 23;24(11):9154. doi: 10.3390/ijms24119154. This announcement has been authorised for release by the Executive Chairperson.
台北訊， Synaptics® 公司 (納斯達克股票代碼: SYNA) 已擴展其獲獎的 Veros™ 三合一連接產品組合，推出 SYN461x 系列超低功耗 (ULP) Wi-Fi® 2.4/5/6 GHz、藍牙® 6.0 和藍牙低功耗 (BLE)，以及 IEEE 802.15.4（Zigbee®/Thread®）系統級晶片 (SoC)。該系列專為嵌入式邊緣 AI 物聯網 (IoT) 設計、應用打造，針對電力效率、系統整合、體積及上市速度進行全面最佳化，並延續 Veros 品牌一貫的遠距離高速傳輸與無縫連接能力。這款多功能且符合 Matter 標準的 SoC 提供先進的藍牙功能，如通道探測（Channel Sounding）和 LE 音訊（包括 Auracast™）。SYN461x 針對消費電子和工業應用，專為穿戴式裝置、智慧手錶、音響耳機、家電設備、監控攝影機、資產追蹤器及工廠自動化應用所設計。 2024 年推出的 Veros 無縫智慧連接解決方案（Veros Seamless Intelligent Connectivity）融合了數十年經過實戰檢驗的技術和物聯網連接專業知識。涵蓋 Synaptics 全系列無線解決方案，具備高效能、良好互通性、優異共存能力、節能設計及元件整合等特色。Veros內建支援 Synaptics Astra™，這是專為物聯網設計的 AI 原生運算平台。 「SYN461x 系列是我們 Veros 產品組合的突破」Synaptics 無線產品行銷副總裁 Vineet Ganju 表示，「這些 SoC 是我們首次從架構層面重新設計，專為超低功耗嵌入式邊緣 AI 物聯網應用量身打造的產品，我們相信其低功耗架構、軟體支援和低密度封裝擴展了我們的廣泛市場覆蓋範圍，使我們能夠分享約 32 億美元的市場商機 。」 「滿足各種多元化低功耗物聯網應用的獨特連接需求所需的多功能性，需要高度的專業領域知識，」IDC 研究總監 Phil Solis 表示，「SYN4612 等超低功耗且高度靈活的解決方案，為需要更多選擇的市場中獨立、專用的無線 SoC 提供了充分理由。」 技術亮點SYN461x 系列將 Synaptics 的三合一系列擴展到超低功耗、高度最佳化的物聯網應用中，在延長電池壽命和最大化範圍的同時，提供高達 50 Mbps 的穩定連線。特點包括：● 支援高達三頻段 1×1 Wi-Fi，涵蓋 2.4、5 和 6 GHz，採用功率最佳化架構● 低功率藍牙/ BLE-具備通道探測功能，可精確測量距離● IEEE 802.15.4（Thread/Zigbee）支持 Matter 標準，實現主流低功耗網路間的無縫互通性● 整合式發射/接收切換器( Tx/Rx switch)、低雜訊放大器(LNAs)和功率放大器(PAs)，可有效降低用料需求與系統成本，並簡化設計流程，僅需直接接上天線即可● 低接腳數 WLBGA 封裝選項，適用於低成本鍍通孔 (PTH) PCB（典型板成本降低 25%）● 整合處理器，卸載主應用處理器，協助最小化系統功耗● Secure Boot to help ensure system integrity● 安全開機功能，有助於確保系統完整性 供貨情況SYN461x 系列現已上市。如需更多資訊：● 取得產品圖片● 下載產品簡介● 聯絡您當地的銷售代表 關於 Synaptics Incorporated Synaptics（納斯達克股票代碼：SYNA）正在推動邊緣 AI 創新，將 AI 更接近終端用戶，改變我們與智慧連接裝置互動的方式，無論是在家中、工作中還是在車載場景中。作為前瞻性產品創新者的首選合作夥伴，Synaptics 透過其尖端的 Synaptics Astra™ AI 原生嵌入式計算、Veros™ 無線連接和多模態感測解決方案為未來提供動力。我們正在使數位體驗變得更智慧、更快速、更直觀、更安全和更流暢。從觸控、顯示和生物識別到 AI 驅動的無線連接、影片、視覺、音訊、語音和安全處理，Synaptics 是推動下一代技術，持續最佳化人們生活、工作和娛樂的體驗的力量。關注 Synaptics 的 LinkedIn、X 和 Facebook，或訪問 www.synaptics.com。
低功耗無線連接領域的創新領導者Silicon Labs (亦稱「芯科科技」，NASDAQ：SLAB)宣佈推出其第三代無線開發平台產品組合首批產品，即採用先進22奈米(nm)製程節點的兩個全新無線系統單晶片(SoC)產品系列：SiXG301和SiXG302。高度整合的解決方案在運算能力、整合度、安全性和能源效率方面實現了重大躍進，可滿足線路供電和電池供電物聯網(IoT)裝置日益成長的需求。 隨著智慧裝置越來越複雜和精巧，對功能強大、安全和高度整合的無線解決方案需求亦空前強烈。全新第三代無線開發平台SoC憑藉先進的處理能力、彈性的記憶體選項、業界最高的安全性和高整合度的精簡外部元件全面實現此承諾。Silicon Labs的第一代、第二代和第三代無線開發平台產品將持續在市場上相輔相成以全面滿足物聯網應用需求。 全新第三代無線開發平台SoC產品包括： • SiXG301：針對線路供電應用而優化 SiXG301專為線路供電的智慧裝置而設計，包括一個整合的LED預驅動器，為先進的LED照明和智慧家庭產品提供理想的解決方案，可支援藍牙、Zigbee和Thread，以及Matter。SiXG301快閃記憶體和RAM容量分別為4 MB和512 kB。隨著Matter和其他要求更嚴苛的物聯網應用需求不斷成長，SiXG301可協助客戶進行因應未來的設計。該SoC能同時實現Zigbee、藍牙和Matter over Thread網路的並行多協定運行，有助於簡化製造SKU、降低成本、節省電路板空間以實現更多元件整合，同時提高消費者可用性。目前已為選定的客戶提供SiXG301批量產品，預計將於2025年第三季度全面供貨。 • SiXG302：專為提高電池供電效率而設計 即將推出的SiXG302將第三代無線開發平台產品擴展至電池供電應用，並且在不犧牲性能的情況下提供突破性的能源效率。SiXG302採用Silicon Labs先進的電源架構，設計僅使用15 µA/MHz的工作電流，比同類產品低30%。這使其成為Matter和藍牙應用中採用電池供電的無線感測器和促動器的理想選擇。SiXG302計畫於2026年提供客戶樣品。 Silicon Labs產品線資深副總裁Ross Sabolcik表示：「智慧裝置正變得越來越複雜，設計人員面臨的挑戰是在保持能源效率的同時，還需將更多功能整合至更小的空間內。藉助SiXG301和即將推出的SiXG302系列產品，我們提供了彈性、高度整合的解決方案以支援下一代物聯網裝置，而無論其運行是透過電纜或電池供電。」 SiXG301和SiXG302系列產品最初將包括用於多重協定的“M”類型元件，即SiMG301和SiMG302，以及針對低功耗藍牙(Bluetooth LE)通訊優化的“B”類型元件SiBG301和SiBG302。 透過將22 奈米製程節點用於所有的第三代無線開發平台產品，Silicon Labs正從智慧城市和工業自動化到醫療保健、智慧家庭等各種物聯網應用領域中，滿足對功能更強大、更高效的遠邊緣(far-edge)裝置日益成長的需求。全新的SoC為裝置製造商提供了一個可擴展且安全的平台，以打造下一波創新的高性能物聯網產品。 透過2025年Works With開發者大會瞭解更多第三代無線開發平台的資訊 欲瞭解更多第三代無線開發平台及其如何推動無線連接發展之資訊，請瀏覽以下網站： • 瞭解更多第三代無線開發平台之資訊 • 瞭解更多SiMG301之資訊 • 瞭解更多SiBG301之資訊 此外，Silicon Labs還將在2025年Works With大會期間重點展示SiXG301，以及業界採用該晶片所開發的各種領先創新產品。此全球性活動彙聚業界專家共同探討最佳實踐、新興技術和影響產業發展的變革性趨勢。Works With大會將於全球多地舉行，並透過線上會議以利更廣泛參與： • Works With峰會：德州奧斯丁: 10月1-2日 • Works With大會深圳站：10月23日 • Works With大會班加羅爾站：10月30日 • Works With線上大會：11月19-20日
SYN461x 在電源效率、系統整合、尺寸和上市時間經過全面最佳化，提供卓越的遠距離傳輸效能與無縫互通能力，鎖定約 32 億美元的市場商機。 台北訊，2025年5月26日 - Synaptics® 公司 (納斯達克股票代碼: SYNA) 已擴展其獲獎的 Veros™ 三合一連接產品組合，推出 SYN461x 系列超低功耗 (ULP) Wi-Fi® 2.4/5/6 GHz、藍牙® 6.0 和藍牙低功耗 (BLE)，以及 IEEE 802.15.4（Zigbee®/Thread®）系統級晶片 (SoC)。該系列專為嵌入式邊緣 AI 物聯網 (IoT) 設計、應用打造，針對電力效率、系統整合、體積及上市速度進行全面最佳化，並延續 Veros 品牌一貫的遠距離高速傳輸與無縫連接能力。這款多功能且符合 Matter 標準的 SoC 提供先進的藍牙功能，如通道探測（Channel Sounding）和 LE 音訊（包括 Auracast™）。SYN461x 針對消費電子和工業應用，專為穿戴式裝置、智慧手錶、音響耳機、家電設備、監控攝影機、資產追蹤器及工廠自動化應用所設計。 2024 年推出的 Veros 無縫智慧連接解決方案（Veros Seamless Intelligent Connectivity）融合了數十年經過實戰檢驗的技術和物聯網連接專業知識。涵蓋 Synaptics 全系列無線解決方案，具備高效能、良好互通性、優異共存能力、節能設計及元件整合等特色。Veros內建支援 Synaptics Astra™，這是專為物聯網設計的 AI 原生運算平台。 「SYN461x 系列是我們 Veros 產品組合的突破」Synaptics 無線產品行銷副總裁 Vineet Ganju 表示，「這些 SoC 是我們首次從架構層面重新設計，專為超低功耗嵌入式邊緣 AI 物聯網應用量身打造的產品，我們相信其低功耗架構、軟體支援和低密度封裝擴展了我們的廣泛市場覆蓋範圍，使我們能夠分享約 32 億美元的市場商機1。」 「滿足各種多元化低功耗物聯網應用的獨特連接需求所需的多功能性，需要高度的專業領域知識，」IDC 研究總監 Phil Solis 表示，「SYN4612 等超低功耗且高度靈活的解決方案，為需要更多選擇的市場中獨立、專用的無線 SoC 提供了充分理由。」 技術亮點 SYN461x 系列將 Synaptics 的三合一系列擴展到超低功耗、高度最佳化的物聯網應用中，在延長電池壽命和最大化範圍的同時，提供高達 50 Mbps 的穩定連線。特點包括： 支援高達三頻段 1×1 Wi-Fi，涵蓋 2.4、5 和 6 GHz，採用功率最佳化架構 低功率藍牙/ BLE-具備通道探測功能，可精確測量距離 IEEE 802.15.4（Thread/Zigbee）支持 Matter 標準，實現主流低功耗網路間的無縫互通性 整合式發射/接收切換器( Tx/Rx switch)、低雜訊放大器(LNAs)和功率放大器(PAs)，可有效降低用料需求與系統成本，並簡化設計流程，僅需直接接上天線即可 低接腳數 WLBGA 封裝選項，適用於低成本鍍通孔 (PTH) PCB（典型板成本降低 25%） 整合處理器，卸載主應用處理器，協助最小化系統功耗 Secure Boot to help ensure system integrity 安全開機功能，有助於確保系統完整性 供貨情況 SYN461x 系列現已上市。如需更多資訊： 取得產品圖片 下載產品簡介 聯絡您當地的銷售代表 關於 Synaptics Incorporated Synaptics（納斯達克股票代碼：SYNA）正在推動邊緣 AI 創新，將 AI 更接近終端用戶，改變我們與智慧連接裝置互動的方式，無論是在家中、工作中還是在車載場景中。作為前瞻性產品創新者的首選合作夥伴，Synaptics 透過其尖端的 Synaptics Astra™ AI 原生嵌入式計算、Veros™ 無線連接和多模態感測解決方案為未來提供動力。我們正在使數位體驗變得更智慧、更快速、更直觀、更安全和更流暢。從觸控、顯示和生物識別到 AI 驅動的無線連接、影片、視覺、音訊、語音和安全處理，Synaptics 是推動下一代技術，持續最佳化人們生活、工作和娛樂的體驗的力量。關注 Synaptics 的 LinkedIn、X 和 Facebook，或訪問 www.synaptics.com。 前瞻性陳述 本新聞稿包含 1995 年《私人證券訴訟改革法案》意義範圍內的前瞻性聲明，包括但不限於與公司當前對 Veros™ 三合一連接產品組合產品和技術（包括 SYN461x）的預期效能和效益相關的當前預期和預測。此類聲明乃根據當前預期所作出，且可能因風險與不確定性而導致實際結果與預期出現重大落差。可能導致實際結果產生差異的因素包括公司成功向新市場（包括 Wi-Fi 和藍牙連接廣泛市場）提供這些產品解決方案的能力；公司對技術和策略投資的預期以及其預期時程或效益；以及公司最新年度報告 10-K 表格和最新季度報告 10-Q 表格的「風險因素」、「管理層對財務狀況和營運成果的討論和分析」和「業務」部分中確定的其他風險；以及公司證券交易委員會報告中不時確定的其他風險。對於本新聞稿中包含的任何前瞻性聲明，公司聲稱享有 1995 年《私人證券訴訟改革法案》中為前瞻性聲明提供的安全港保護，且公司不承擔公開更新或修改前瞻性聲明的義務，以反映新資訊或未來事件，除非法律要求。 Synaptics和Synaptics標誌是Synaptics在美國和/或其他國家的商標。所有其他標誌均為其各自所有者的財產。
TAIPEI, May 21, 2025 /PRNewswire/ -- ASPEED Technology unveils its next-generation AST1800 system-on-chip (SoC) at COMPUTEX 2025, building on the success of the AST1700 I/O Expander while integrating advanced eFPGA (programmable logic SoC) technology. This innovation simplifies server design and boosts performance, setting the stage for the next generation of server architecture. At the same time, ASPEED's subsidiary, Cupola360 Inc., debuts with its next-generation Cupola360 Smart Patrol Camera RX2000, powered by the latest SoC, under the theme "Eyes of AI." Additionally, it collaborates with multiple partners to showcase a series of standardized solutions that can be quickly deployed and offer high flexibility, built around the concept of "AIoT-driven smart manufacturing." This highlights Cupola360's continued dedication to creating a comprehensive 360-degree camera ecosystem. Recognizing the trend towards modular server design, the new AST1800 SoC builds on the AST1700 I/O Expander, which seamlessly integrates with the 8th generation AST2700 Baseboard Management Controller (BMC) to streamline design and reduce power consumption. The AST1800 SoC takes these advantages to the next level with a groundbreaking design, extending high-performance I/O modules and delivering up to 1Gb/s bandwidth through LTPI technology, supporting a broad range of I/O and data transfer needs, making it ideal for high-density server environments. Furthermore, the AST1800 integrates eFPGA architecture for custom logic functions, such as GPIO control and protocol conversion, providing exceptional flexibility in system design. Equipped with OCP M-PESTI and eSPI buses, the AST1800 provides comprehensive tools for logic synthesis, programming, debugging, and logic analysis, optimizing both hardware and software development processes. Its compact 21x21mm package design offers high integration and cost-efficiency, making it a powerful and scalable solution for data centers and edge computing devices. Mass production is expected to begin in 2027. Under the theme "Advancing Towards Diverse Applications," ASPEED presents a wide range of solutions featuring the AST2600 BMC and the AST1060 PRoT Security SoC. These products showcase ASPEED's extensive expertise in cloud applications and integration, covering diverse environments such as compute node servers, switches, power shelves, cooling management, smart NICs, edge AI, networking, and AI VFF servers. This broad portfolio highlights ASPEED's strategy to evolve from a single remote server management SoC towards a more diversified product layout, increasing product penetration among customers and expanding its product lineup. This demonstrates strong innovation momentum and market competitiveness, which will also drive greater growth for ASPEED. Furthermore, centered around the theme "Eyes of AI," Cupola360 showcases the new Cupola360 Smart Patrol Camera RX2000, which supports 8K@15 ultra-high-definition panoramic imagery, NDAA certification, built-in cybersecurity, edge AI computing, and an extensible open AI platform. The camera provides real-time data analysis and decision-making capabilities, making it distinctly different from traditional surveillance cameras, with each Cupola360 camera acting as a remote "on-site digital twin" This opens up vast opportunities for applications. Equipped with the Cupola360⁺ Patrol System, it integrates 360-degree panoramic imaging with AI-powered autonomous patrol, bringing a complete revolution to proactive security across industries. The system features AI-driven capabilities such as real-time inspections, fire and smoke detection, crowd monitoring, and behavior analysis, along with several extensible AI functions. The patrol system also supports integration with traditional surveillance cameras, acting as a "Spatial Commander" by merging 360-degree panoramic images with conventional video feeds, displayed through a picture-in-picture format. This not only immediately fills in blind spots and provides a comprehensive spatial view but also creates a perfect complement to traditional systems. In contrast to conventional split-screen surveillance systems, which are predominantly used for post-incident video playback, the addition of the "Spatial Commander" and "on-site digital twin" concepts in Cupola360 offers real-time prevention, disaster reduction, enhanced efficiency, and reduced manpower and costs. This effectively transforms surveillance from "post-event review" to "real-time prevention." Cupola360 also collaborates with several partners to launch standardized solutions that integrate the features described above, which have already been practically applied. These solutions help businesses build smart systems in less time and with greater efficiency, while meeting the digital upgrading needs across industries such as smart factory patrol and management, smart healthcare, physical security for data centers, and smart city applications. These solutions not only lower deployment barriers but also provide high compatibility, flexibility, and scalability with open-platform technology support. Whether it's factories, smart buildings, data centers, traffic monitoring, or retail spaces, Cupola360's platform enables rapid deployment and stable operation, making it a crucial tool for the fastest digital transformation results across industries. For more details, please visit ASPEED Technology's booth M1220, 4th floor, Hall 1, Taipei Nangang Exhibition Center. About ASPEED Technology Founded in 2004, ASPEED Technology specializes in innovative SoC solutions. In 2016, ASPEED acquired Broadcom's Emulex Pilot™ server remote management chip business, becoming the world's leading supplier of remote server management SoCs. ASPEED's R&D spans two major product lines: Cloud & Enterprise Solutions and Smart AV Solutions. The Cloud & Enterprise Solutions include Baseboard Management Controller (BMC) SoCs, Bridge IC (BIC), I/O Expander, and PRoT IC. The Smart AV Solutions feature the Cupola360 panoramic cameras, Cupola360 panoramic image processors, AVoIP SoCs, video conferencing SoCs, and Cupola360+ software. Since 2014, ASPEED has been recognized for ten consecutive years in Forbes' "Asia's 200 Best Under a Billion" list, earning the "Decade of Success" award. ASPEED has established itself as a trusted partner, and in both 2023 and 2024, it was ranked first in the "All Asia Executive Team - Semiconductor" category by Institutional Investor, a leading U.S. financial media and research institution. ASPEED's Chairman and President, Mr. Chris Lin, was also named Best CEO in Asia. For more information, visit: www.aspeedtech.com About Cupola360 Inc. Cupola360 Inc., founded in 2018, is a subsidiary of ASPEED Technology, a leading IC design company. Cupola360 is dedicated to providing comprehensive 360-degree panoramic imaging solutions, delivering a seamless, zero-latency, and immersive first-person experience with no blind spots. By leveraging ASPEED's Cupola360 panoramic image processors, Cupola360 has launched a series of panoramic cameras and related deployment software. The company collaborates with AI service providers, system integrators, distributors, and other ecosystem partners to offer panoramic smart visual remote management solutions. These solutions cover applications such as smart patrol, smart city, and video conferencing. For more information, please visit: https://cupola360.com/en/
當前市場中，物料清單（BOM）成本持續攀升，開發者需在效能和預算間實現優化。鑑於中階FPGA市場很大一部分無需整合串列收發器，Microchip Technology Inc.正式發佈PolarFire® Core FPGA和SoC。新元件是基礎 PolarFire 系列的衍生產品，透過優化功能並移除整合收發器，將客戶成本降低多達 30%。Core 元件提供與經典 PolarFire 技術相同的行業領先低功耗特性，以及經過驗證的安全性和可靠性，在實現成本節約的同時，不犧牲功能、處理能力或品質。 PolarFire Core 系列專爲汽車、工業自動化、醫療、通訊、國防和航太市場設計，具備單粒子翻轉（SEU）免疫能力，確保關鍵任務所需的高度可靠性，並整合四核心 64 位元 RISC-V® 微處理器（MPU），提供彈性的運算能力。此外，Core 裝置設計上與全系列 PolarFire FPGA 採用接腳對接相容，可靈活因應不同設計版本（SKU）需求，進一步提升在重視成本效益、但不需要過多功能的應用場景中的價值。 Microchip FPGA業務部門企業副總裁Bruce Weyer表示：「許多 FPGA 同業近期紛紛調漲價格，對於需要快速推動產品上市，並同時達成最低成本與功耗目標的OEM商而言，帶來了新的挑戰。我們的 PolarFire Core FPGA 與 SoC 系列正面迎戰這些成本與功耗預算挑戰，提供具市場領先地位、且具價格競爭力的解決方案。」 無論是實現即時控制、邊緣處理還是安全關鍵系統，PolarFire Core元件旨在爲工程師提供加速創新所需的靈活性與持久性。請存取官網瞭解更多Microchip FPGA和SoC產品組合。 開發工具 PolarFire Core元件相容Microchip的Libero® SoC設計工具套件、SmartHLS™編譯器、VectorBlox™加速器SDK，以及用於快速開發RISC-V應用的Mi-V合作伙伴平台生態系統。它們可與現有PolarFire FPGA和SoC開發板相容，加速晶片開發流程。 供貨與定價 如需購買或獲取更多訊息，請聯繫Microchip業務代表、授權全球經銷商，或存取Microchip採購與客戶服務網站：www.microchipdirect.com 。
A12 藝術空間
SoC
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
